Evidence map›Paper›PMID 35582045›Full record

ArticleCancer drug resistance (Alhambra, Calif.)2020

Circulating tumor cells and drug history in primary breast cancer patients.

Silvia Jurisova, Marián Karaba, Gabriel Minarik, Juraj Benca, Tatiana Sedlackova, Daniela Manasova, Katarina Kalavska, Daniel Pindak, Jozef Mardiak, Michal Mego

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer drug resistance (Alhambra, Calif.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Concomitant medications and circulating tumor cells: friends or foes?Cancer drug resistance (Alhambra, Calif.) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Silvia Jurisova2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava 83310, Slovakia.
Marián KarabaNational Cancer Institute, Bratislava 83310, Slovakia.
Gabriel MinarikInstitute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Bratislava 83172, Slovakia.
Juraj BencaNational Cancer Institute, Bratislava 83310, Slovakia.
Tatiana SedlackovaInstitute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Bratislava 83172, Slovakia.
Daniela Manasova2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava 83310, Slovakia.
Katarina Kalavska2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava 83310, Slovakia.
Daniel PindakNational Cancer Institute, Bratislava 83310, Slovakia.
Jozef Mardiak2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava 83310, Slovakia.
Michal Mego2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava 83310, Slovakia.
National Cancer Institute · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

chronic medicationCirculating tumor cellsearly breast cancerepithelial-to-mesenchymal transition

Identifiers

PMID35582045
PMCPMC9094054
OpenAlexW3006336462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.